Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.

ABSTRACT:

Objective

To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.

Design

Retrospective, propensity matched cohort study.

Setting

Optum Labs Data Warehouse, a large database including administrative claims data on privately insured and Medicare Advantage enrollees.

Participants

New users of dabigatran, rivaroxaban, and warfarin from 1 November 2010 to 30 September 2013.

Main outcome measures

Incidence rates (events/100 patient years) and propensity score matched Cox proportional hazards models were used to estimate rates of total gastrointestinal bleeds, upper gastrointestinal bleeds, and lower gastrointestinal bleeds for the novel oral antico

SUBMITTER: Abraham NS 

PROVIDER: S-EPMC4413863 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature